Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

J. Pablo Arnoletti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-8757-4398; OpenAlex author ID A5063519178. Sources: ClinicalTrials.gov.

Their work

Papers
12 (first author 2, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 3 papers · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 12

  1. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  2. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-25-0237↗
  3. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Co-author DOI 10.3389/fonc.2024.1362244↗
  4. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal… Co-author DOI 10.1371/journal.pone.0265725↗
  5. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  6. Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation. Co-author DOI 10.1097/mpa.0000000000000667↗
  7. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Co-author DOI 10.1038/onc.2015.126↗
  8. Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0078183↗
  9. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. First author DOI 10.6004/jnccn.2012.0073↗
  10. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally… Co-author DOI 10.1007/s00280-010-1383-0↗
  11. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. First author DOI 10.1038/bjc.2011.263↗
  12. Serum biomarker panels for the detection of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-10-0248↗

Trials 1

  1. 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients Principal investigator NCT00841035↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mokenge Peter Malafa · 3 shared papers, 2012–2025 · strength 0.33
  2. Sarah M. Judge · 2 shared papers, 2025 · strength 0.31
  3. Daniel K. Jeong · 2 shared papers, 2025 · strength 0.31
  4. Nathan H. Parker · 2 shared papers, 2025 · strength 0.31
  5. Andrew R. Judge · 2 shared papers, 2025 · strength 0.31
  6. Dung‐Tsa Chen · 2 shared papers, 2025 · strength 0.31
  7. Evan W. Davis · 2 shared papers, 2025 · strength 0.31
  8. José M. Pimiento · 2 shared papers, 2025 · strength 0.31
  9. Vic Velanovich · 2 shared papers, 2025 · strength 0.31
  10. Paul A. Stewart · 2 shared papers, 2025 · strength 0.31
  11. Margaret A. Park · 2 shared papers, 2025 · strength 0.31
  12. Jason B. Fleming · 2 shared papers, 2025 · strength 0.31
  13. Jose Gilberto Trevino · 2 shared papers, 2025 · strength 0.31
  14. Sylvia L. Crowder · 2 shared papers, 2025 · strength 0.31
  15. Pamela Joy Hodul · 2 shared papers, 2025 · strength 0.31
  16. Ghulam Rasool · 2 shared papers, 2025 · strength 0.31
  17. Jennifer B. Permuth · 2 shared papers, 2025 · strength 0.31
  18. Sally A. Litherland · 2 shared papers, 2017–2022 · strength 0.20
  19. Nipun B. Merchant · 2 shared papers, 2012–2025 · strength 0.17
  20. Kun Jiang · 1 shared paper, 2025 · strength 0.16
  21. Shaffer R. S. Mok · 1 shared paper, 2025 · strength 0.16
  22. for the Florida Pancreas Collaborative · 1 shared paper, 2025 · strength 0.16
  23. Dae Won Kim · 1 shared paper, 2025 · strength 0.16
  24. Kenneth Lee Meredith · 1 shared paper, 2025 · strength 0.15
  25. Otto Phanstiel · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.